Clinical trial to evaluate the safety of Temsirolimus combined with Vincristine and Irinotecan in children with recurrent/refractory solid tumors

Clinical trial to evaluate the safety of Temsirolimus combined with Vincristine and Irinotecan in children with recurrent/refractory solid tumors - Clinical trial to evaluate the safety of Temsirolimus combined with Vincristine and Irinotecan in children with recurrent/refractory solid tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017453

Enrollment

Registered

2015-05-07

Start date

2013-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

childhood recurrent/refractory solid malignant tumors

Interventions

Vincristin Irinotecan Temsilorimus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: recurrent/ reflactory childhood solid malignant tumors: neuroblastomaneuroblastoma, rhabdomyosarcoma, undifferentiated sarcoma, Ewing family tumor, retinoblastoma, nephroblastoma, hepatoblastoma, osteosarcoma, others (including brain tumors)

Exclusion criteria

Exclusion criteria: active double cancer severe infection abnormal ECG findings intestinal pneumonia etc.

Design outcomes

Primary

Measure	Time frame
Dose limiting toxicity of temusirolimus with the combination therapy of vincristin and irinotecan	—

Secondary

Measure	Time frame
Response rates and adverse eventsin vincristin/irinotecan/temusirolimus combination study	—

Countries

Japan

Contacts

Public ContactSho Kurihara

Hiroshima University Hospital Pediatric Surgery

jplt@hiroshima-u.ac.jp082-257-5416

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026